ID
11638
Descripción
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis ODM derived from http://clinicaltrials.gov/ct2/show/NCT00148213?term=NCT00148213&rank=1
Link
http://clinicaltrials.gov/ct2/show/NCT00148213?term=NCT00148213&rank=1
Palabras clave
Versiones (2)
- 24/11/11 24/11/11 -
- 9/7/15 9/7/15 - Martin Dugas
Subido en
9 de julio de 2015
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Psoriasis NCT00216879
Eligibility Psoriasis NCT00216879
- StudyEvent: Eligibility
Descripción
Exclusion Criteria
Alias
- UMLS CUI-1
- C0680251
Descripción
PUVA or Grenz ray therapy anywhere on the patient within 28 days prior to randomisation
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0853073
- UMLS CUI-2
- C0018233
Descripción
UVB therapy anywhere on the patient within 14 days prior to randomisation
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0564461
Descripción
Systemic use of biological treatments, whether marketed or not, directed against or with a potential effect on, scalp psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab) within 6 months prior to randomisaiton
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0005522
Descripción
Systemic treatments with a potential effect on scalp psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within 28 days prior to randomisation
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C1515119
Descripción
Any topical treatment for scalp psoriasis or any other skin disease on the scalp (excluding medicated shampoos, emollients and hair conditioners) within 14 days prior to randomisaiton
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0150349
Descripción
Topical treatment for other skin disorders with very potent WHO group IV corticosteroids within 14 days prior to randomisation
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0150349
- UMLS CUI-2
- C0001617
Descripción
Planned initiation of, or changes in dose of concomitant medication that could affect scalp psoriasis (e.g., beta blockers, antimalarial drugs, lithium) during the study
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C2347852
Descripción
Current diagnosis of guttate, pustular, exfoliative or erythrodermic psoriasis
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0343052
- UMLS CUI-2
- C0152081
- UMLS CUI-3
- C0748052
Descripción
Patients with any of the following conditions present on the scalp area: viral lesions, fungal and bacterial skin infections, parasitic infections and atrophic skin
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0037278
Descripción
Known or suspected severe renal insufficiency or severe hepatic disorders
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C1565489
- UMLS CUI-2
- C1869009
Descripción
Patiens with history/signs/symptoms suggestive of an abnormality of calcium homeostasis associated with clinically significant hypercalcaemia
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0020437
Descripción
Trial subjects should be using an adequate method of contraception
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0700589
Similar models
Eligibility Psoriasis NCT00216879
- StudyEvent: Eligibility
C0018233 (UMLS CUI-2)
C0001617 (UMLS CUI-2)
C0152081 (UMLS CUI-2)
C0748052 (UMLS CUI-3)
C1869009 (UMLS CUI-2)